LeadArt Biotechnologies (www.leadartech.com) is revolutionizing drug discovery and development by pioneering automation in chemoproteomics. Our cutting-edge platform seamlessly integrates chemoproteomics and advanced automation technologies, enabling the rapid generation of high-quality, large-scale protein-drug target profiling data.

With a proprietary live-cell protein-probe interaction database, targeting over 15,000 human proteome proteins, and an AI-enhanced analytics platform, we empower biotech and pharmaceutical companies to accelerate drug discovery for undruggable and challenging targets.

Our proprietary Target Space Station™ system provides high-throughput, live-cell assays and screenings tailored to individual needs. This innovative platform not only enables fast and cost-effective hit discovery and lead optimization but also offers customized construction of target-ligand interaction databases. These databases deliver large-scale, reliable data critical for advancing drug discovery projects, especially for AI-augmented pharmaceutical development.

Our automation solutions further streamline research processes:

• Hive™: A scalable automated sample management system capable of managing up to 5,000 samples per unit, expandable through networked integration.
• Eve™ Automated Cell Workstation: Fully automates cell handling, processing up to 150 T75 flasks per day, eliminating manual labor.
• Cube™ Automated Incubator: Versatile for diverse automated cell culture workflows, with integrated microscopy for real-time cell monitoring.

At LeadArt Biotechnologies, we are committed to transforming the future of drug discovery through innovation, precision, and efficiency.